Building body of knowledge on intranasal vaccination
A story about how a P1 clinical trial evaluating intranasal delivery of AstraZeneca COVID-19 vaccine failed to generate a strong immune response also proved of great interest to readers.
Oxford University researchers found that antigen-specific mucosal antibody responses to intranasal vaccination were detectable in a minority of participants, rarely exceeding levels seen after SARS-CoV-2 infection.
The team involved in the researchers were nevertheless encouraged by the acceptable safety profile of the vaccine: and believe their findings, alongside other licensed or candidate vaccines, can help build up a body of knowledge.
Photo credit: GettyImages/lakshmiprasad S
